Maven Securities LTD Decreases Position in OKYO Pharma Limited Sponsored ADR $OKYO

Maven Securities LTD lessened its stake in OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) by 31.2% during the second quarter, HoldingsChannel reports. The firm owned 809,317 shares of the company’s stock after selling 366,218 shares during the period. Maven Securities LTD’s holdings in OKYO Pharma were worth $1,214,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also bought and sold shares of the company. Citadel Advisors LLC bought a new position in OKYO Pharma during the third quarter valued at $31,000. XTX Topco Ltd purchased a new stake in OKYO Pharma in the fourth quarter worth $36,000. Finally, Renaissance Technologies LLC increased its position in OKYO Pharma by 235.0% in the fourth quarter. Renaissance Technologies LLC now owns 138,000 shares of the company’s stock worth $286,000 after buying an additional 96,800 shares during the last quarter. Hedge funds and other institutional investors own 2.97% of the company’s stock.

OKYO Pharma Stock Down 2.5%

OKYO opened at $1.53 on Wednesday. OKYO Pharma Limited Sponsored ADR has a 12 month low of $1.34 and a 12 month high of $3.20. The company has a 50 day moving average of $1.56 and a 200 day moving average of $1.60.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of OKYO Pharma in a research report on Friday, July 17th. HC Wainwright lowered their price objective on OKYO Pharma from $7.00 to $5.00 and set a “buy” rating on the stock in a research note on Monday, July 13th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $5.67.

About OKYO Pharma

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.